Eaton Vance Worldwide Health Sciences Fund R (ERHSX)
16.36
-0.13
(-0.79%)
USD |
Nov 16 2026
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.43% | 852.23M | 1.64% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -122.87M | 15.00% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
63
-258.69M
Peer Group Low
40.23M
Peer Group High
1 Year
% Rank:
60
-122.87M
-4.152B
Peer Group Low
118.44M
Peer Group High
3 Months
% Rank:
67
-781.12M
Peer Group Low
95.26M
Peer Group High
3 Years
% Rank:
41
-15.96B
Peer Group Low
379.82M
Peer Group High
6 Months
% Rank:
80
-1.898B
Peer Group Low
239.17M
Peer Group High
5 Years
% Rank:
41
-21.94B
Peer Group Low
451.06M
Peer Group High
YTD
% Rank:
63
-3.299B
Peer Group Low
1.026B
Peer Group High
10 Years
% Rank:
64
-42.70B
Peer Group Low
814.82M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of November 17, 2026.
Asset Allocation
As of September 30, 2026.
| Type | % Net |
|---|---|
| Cash | 0.03% |
| Stock | 99.64% |
| Bond | 0.02% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.31% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 12.38% | 1406.48 | -1.76% |
| AbbVie, Inc. | 7.55% | 292.45 | -0.71% |
| Johnson & Johnson | 7.37% | 278.76 | -1.34% |
| Merck & Co., Inc. | 6.05% | 143.49 | -0.67% |
| Roche Holding AG | 5.23% | 483.84 | -0.75% |
| UnitedHealth Group, Inc. | 5.15% | 391.41 | -5.00% |
| AstraZeneca PLC | 4.43% | 182.41 | -0.87% |
| Bristol Myers Squibb Co. | 4.11% | 60.82 | -3.35% |
| Vertex Pharmaceuticals, Inc. | 3.80% | 533.92 | -0.72% |
| Thermo Fisher Scientific, Inc. | 3.57% | 689.12 | -0.32% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.50% |
| Actual Management Fee | 0.77% |
| Administration Fee | 84713.00 None |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 0.00 None |
TTM Distributions
| Type | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of October 31, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (11-16-26) | 0.20% |
| 30-Day SEC Yield (12-31-24) | 55.80M% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 43 |
| Stock | |
| Weighted Average PE Ratio | 34.15 |
| Weighted Average Price to Sales Ratio | 6.918 |
| Weighted Average Price to Book Ratio | 8.974 |
| Weighted Median ROE | 508.2% |
| Weighted Median ROA | 9.25% |
| Return on Investment (TTM) | 13.27% |
| Earning Yield | 0.0345 |
| LT Debt / Shareholders Equity | 0.7868 |
| Number of Equity Holdings | 41 |
As of September 30, 2026
Growth Metrics
| EPS Growth (1Y) | 37.06% |
| EPS Growth (3Y) | 13.55% |
| EPS Growth (5Y) | 14.66% |
| Sales Growth (1Y) | 14.49% |
| Sales Growth (3Y) | 10.47% |
| Sales Growth (5Y) | 11.23% |
| Sales per Share Growth (1Y) | 16.73% |
| Sales per Share Growth (3Y) | 11.13% |
| Operating Cash Flow - Growth Rate (3Y) | 6.69% |
As of September 30, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:ERHSX", "name") |
| Broad Asset Class: =YCI("M:ERHSX", "broad_asset_class") |
| Broad Category: =YCI("M:ERHSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:ERHSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |